GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beijing Luzhu Biotechnology Co Ltd (HKSE:02480) » Definitions » Cash per Share

Beijing Luzhu Biotechnology Co (HKSE:02480) Cash per Share : HK$4.04 (As of Jun. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Beijing Luzhu Biotechnology Co Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Beijing Luzhu Biotechnology Co's Cash per Share for the quarter that ended in Jun. 2023 was HK$4.04.

Beijing Luzhu Biotechnology Co Cash per Share Historical Data

The historical data trend for Beijing Luzhu Biotechnology Co's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Luzhu Biotechnology Co Cash per Share Chart

Beijing Luzhu Biotechnology Co Annual Data
Trend Dec21 Dec22 Dec23
Cash per Share
3.41 3.21 3.29

Beijing Luzhu Biotechnology Co Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Cash per Share 3.41 - 3.21 4.04 3.29

Beijing Luzhu Biotechnology Co Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Beijing Luzhu Biotechnology Co's Cash per Share for the fiscal year that ended in Dec. 2022 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=649.526/202.45
=3.21

Beijing Luzhu Biotechnology Co's Cash per Share for the quarter that ended in Jun. 2023 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=818.336/202.45
=4.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beijing Luzhu Biotechnology Co  (HKSE:02480) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Beijing Luzhu Biotechnology Co Cash per Share Related Terms

Thank you for viewing the detailed overview of Beijing Luzhu Biotechnology Co's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Beijing Luzhu Biotechnology Co (HKSE:02480) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beijing Luzhu Biotechnology Co Ltd (HKSE:02480) » Definitions » Cash per Share
Comparable Companies
HKSE:00775 HKSE:02696 HKSE:02157 HKSE:06855 HKSE:02171 HKSE:02487 HKSE:06955 HKSE:02315 HKSE:02105 HKSE:02179 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
No. 3 Guangtong Street, Industrial Development Zone, Zhangjiawan Tongzhou District, Beijing, CHN
Website
http://www.luzhubiotech.com
Beijing Luzhu Biotechnology Co Ltd is a biotechnology company committed to developing innovative human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. Its clinical-stage product candidates comprise one vaccine candidate, LZ901 and two antibody injection product candidates, including K3 and K193. LZ901 is our Core Product.
Executives
Ma Jianan 2201 Interest of corporation controlled by you
Zhu Hai Heng Qin Lv Zhu Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Bei Jing Lv Zhu Kang Rui Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Bei Jing Sai Sheng Yao Ye Gu Fen You Xian Gong Si 2101 Beneficial owner
Bei Jing Yi Zhuang Er Qi Sheng Wu Yi Yao Chan Ye Tou Zi Ji Jin You Xian He Huo 2101 Beneficial owner
Bei Jing Yi Zhuang Sheng Wu Yi Yao Bing Gou Tou Zi Zhong Xin You Xian He Huo 2101 Beneficial owner
Tian Jin Sai Ding Fang De Zi Chan Guan Li Zhong Xin 2201 Interest of corporation controlled by you
Tian Jin Sai De Rui Bo Zi Chan Guan Li Zhong Xin 2201 Interest of corporation controlled by you
Bei Jing Yi Tang Sai Ying Ji Jin Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
China Construction Bank Corporation 2201 Interest of corporation controlled by you
Central Huijin Investment Ltd. 2201 Interest of corporation controlled by you
Peng Ling 2201 Interest of corporation controlled by you
Zhang Yanping 2202 Interest of your spouse
Kong Jian 2101 Beneficial owner
Ma Biao 2201 Interest of corporation controlled by you

Beijing Luzhu Biotechnology Co (HKSE:02480) Headlines

No Headlines